{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:39:18Z","timestamp":1784907558462,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Loco-regional recurrence (LRR) of esophageal cancer following esophagectomy presents a significant therapeutic problem. This study aimed to evaluate the effectiveness of salvage concurrent chemoradiotherapy (CCRT) and to identify the prognostic factors influencing the survival outcomes in patients with an LRR of esophageal cancer. Methods: This retrospective study included 68 patients who underwent salvage CCRT for an LRR of esophageal squamous cell carcinoma between April 2008 and June 2024. Patients were treated with either 50.4 Gy in 28 fractions or 60 Gy in 30 fractions, along with concurrent fluoropyrimidine- and platinum-based chemotherapy. Prognostic factors were identified using univariate and multivariate Cox proportional hazards models. Results: The median overall survival (OS) was 30.1 months (95% confidence interval [CI]: 21.5\u2013110.7 months), with a 2-year OS rate of 57.4%. The median progression-free survival (PFS) was 8.9 months (95% CI: 6.3\u201317.7 months). In the multivariate analysis, the significant prognostic factors for OS included the interval to recurrence (&gt;1 year vs. \u22641 year, hazard ratio [HR] = 2.307, p = 0.024) and radiotherapy dose (60 Gy vs. 50.4 Gy, HR = 2.414, p = 0.040). For PFS, the interval to recurrence and radiotherapy dose remained significant predictors (p &lt; 0.05). The 2-year OS rate was higher in the 60 Gy arm (62.7% vs. 42.0%, p = 0.285) and in patients with recurrence occurring &gt;1 year after surgery (73.4% vs. 29.9%, p = 0.0054). The local control rate at 2 years was 71.9%, with better outcomes observed in the 60 Gy arm (93.5% vs. 76.5%, p = 0.0651). Conclusions: Salvage CCRT is a viable treatment option for LRR of esophageal cancer, achieving favorable survival outcomes, particularly in patients with late recurrence (&gt;1 year) and in those receiving higher radiotherapy doses.<\/jats:p>","DOI":"10.3390\/jcm14051540","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:45:08Z","timestamp":1740469508000},"page":"1540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Salvage Chemoradiotherapy for Loco-Regional Recurrence of Esophageal Squamous Cell Carcinoma After Esophagectomy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-1828","authenticated-orcid":false,"given":"Atsuto","family":"Katano","sequence":"first","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kiritoshi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Nerima Hikarigaoka Hospital, 2-11-1 Hikarigaoka, Nerima-Ku, Tokyo 179-0072, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subaru","family":"Sawayanagi","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideomi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Radiology, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, Y., Peng, L., and Zhang, L. (2022). Research Progress on the Predicting Factors and Coping Strategies for Postoperative Recurrence of Esophageal Cancer. Cells, 12.","DOI":"10.3390\/cells12010114"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S1643","DOI":"10.21037\/jtd.2019.06.76","article-title":"Locoregional and oligometastatic recurrence of esophageal cancer-what are the management strategies?","volume":"11","author":"Sudarshan","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"ref_3","first-page":"949","article-title":"Prognostic factors in patients with recurrence after complete resection of esophageal squamous cell carcinoma","volume":"6","author":"Su","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S1292","DOI":"10.1245\/s10434-015-4840-5","article-title":"Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent","volume":"22","author":"Parry","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sugawara, K., Oka, D., Hara, H., Yoshii, T., Ushijima, H., Kudo, S., and Fukuda, T. (2023). Survival outcomes of esophageal cancer patients with recurrence after curative treatments. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11568-w"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mitamura, A., Tsujinaka, S., Nakano, T., Sawada, K., and Shibata, C. (2024). Treatment Strategies for Locoregional Recurrence in Esophageal Squamous-Cell Carcinoma: An Updated Review. Cancers, 16.","DOI":"10.3390\/cancers16142539"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.21037\/tgh.2020.01.10","article-title":"Systemic therapy for advanced gastroesophageal cancers: Progress and pitfalls","volume":"5","author":"Epistola","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/jjco\/hyz034","article-title":"Systemic treatment of advanced esophageal squamous cell carcinoma: Chemotherapy, molecular-targeting therapy and immunotherapy","volume":"49","author":"Hirano","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/CMAR.S35785","article-title":"Nedaplatin: A cisplatin derivative in cancer chemotherapy","volume":"5","author":"Shimada","year":"2013","journal-title":"Cancer Manag. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100565","DOI":"10.1016\/j.esmoop.2022.100565","article-title":"A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer","volume":"7","author":"Yang","year":"2022","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jtho.2018.07.006","article-title":"Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung\u2014A Multicenter, Open-label, Randomized, Phase III Trial","volume":"13","author":"Lu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/sj.bjc.6604332","article-title":"The role of S-1 in the treatment of gastric cancer","volume":"98","author":"Kubota","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.23.02167","article-title":"Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY","volume":"42","author":"Kang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Endo, S., Terazawa, T., Goto, M., Tanaka, R., Kato, T., Fujitani, K., Kawakami, H., Sakai, D., Kurokawa, Y., and Tsujinaka, T. (2022). Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): Protocol of a multi-center, phase II study. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09890-w"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/jcrt.JCRT_338_17","article-title":"Successful definitive concurrent chemoradiotherapy in a patient with esophageal cancer and Child-Pugh B cirrhosis of the liver","volume":"15","author":"Katano","year":"2019","journal-title":"J. Cancer Res. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4143\/crt.2024.191","article-title":"Salvage Radiotherapy for Loco-Regional Recurrence of Esophageal Cancer Following Surgery","volume":"57","author":"Cho","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jjco\/hyae124","article-title":"Salvage radiotherapy for locoregional recurrence of esophageal cancer after surgery","volume":"55","author":"Torii","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10388-022-00936-3","article-title":"Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil\/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma","volume":"19","author":"Ito","year":"2022","journal-title":"Esophagus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"doab020","DOI":"10.1093\/dote\/doab020","article-title":"Salvage radiotherapy for postoperative locoregional failure in esophageal cancer: A systematic review and meta-analysis","volume":"35","author":"Mummudi","year":"2022","journal-title":"Dis. Esophagus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15330338241229363","DOI":"10.1177\/15330338241229363","article-title":"Recent Advances and Challenges in Stereotactic Body Radiotherapy","volume":"23","author":"Katano","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_23","first-page":"1061","article-title":"Stereotactic body radiotherapy for oligo-recurrence in the liver in a patient with esophageal carcinoma: A case report","volume":"7","author":"Katano","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.21873\/anticanres.14164","article-title":"Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors","volume":"40","author":"Yamamoto","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Seyedin, S.N., Gannon, M.K., Plichta, K.A., Abushahin, L., Berg, D.J., Arshava, E.V., Parekh, K.R., Keech, J.C., Caster, J.M., and Welsh, J.W. (2020). Safety and Efficacy of Stereotactic Body Radiation Therapy for Locoregional Recurrences After Prior Chemoradiation for Advanced Esophageal Carcinoma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01311"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.athoracsur.2005.03.099","article-title":"Locally recurrent esophageal carcinoma: When is re-resection indicated?","volume":"80","author":"Schipper","year":"2005","journal-title":"Ann. Thorac. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.23.02009","article-title":"Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial","volume":"42","author":"Jia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.18.02122","article-title":"Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial","volume":"37","author":"Chen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13014-023-02339-9","article-title":"Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: Long-term follow-up results of a phase II randomized controlled trial","volume":"18","author":"Jiang","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","article-title":"INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy","volume":"20","author":"Minsky","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ijrobp.2022.11.006","article-title":"High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial","volume":"115","author":"You","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:11Z","timestamp":1760028131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051540"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051540","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]}}}